has been cited by the following article(s):
|
[1]
|
Management of Recurrent Uterine Cervical Cancer
|
|
2019 |
|
|
|
|
[2]
|
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
|
|
2018 |
|
|
|
|
[3]
|
Shades of chemical beauty: An overview of synthetic routes to some anticancer drugs
|
|
Synthetic Communications,
2017 |
|
|
|
|
[4]
|
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
|
|
Critical Reviews in Oncology/Hematology,
2016 |
|
|
|
|
[5]
|
Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic …
|
|
Journal of Clinical Oncology,
2014 |
|
|
|
|
[6]
|
Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: A limited access phase II trial of the Gynecologic Oncology Group
|
|
Journal of Clinical Oncology,
2014 |
|
|
|
|
[7]
|
Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a
|
|
Case reports in oncology,
2014 |
|
|
|
|
[8]
|
Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
|
|
Case reports in oncology,
2014 |
|
|
|
|
[1]
|
Uterine Cervical Cancer
2019
DOI:10.1007/978-3-030-02701-8_11
|
|
|
|
|
[2]
|
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
Oncology Reviews,
2018
DOI:10.4081/oncol.2018.346
|
|
|
|
|
[3]
|
Shades of chemical beauty: An overview of synthetic routes to some anticancer drugs
Synthetic Communications,
2017
DOI:10.1080/00397911.2017.1324627
|
|
|
|
|
[4]
|
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
Critical Reviews in Oncology/Hematology,
2016
DOI:10.1016/j.critrevonc.2016.11.006
|
|
|
|
|
[5]
|
Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group
Journal of Clinical Oncology,
2014
DOI:10.1200/JCO.2013.54.7448
|
|
|
|
|
[6]
|
Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
Case Reports in Oncology,
2014
DOI:10.1159/000365885
|
|
|
|